We first examined the relative potency of alectinib and SHP099 in ALK+ lung adenocarcinoma cells; H3122 (ALK+ variant 1) and H2228 (ALK+ variant 3) cells were highly sensitive to alectinib, with EC50 values of 0.018 μM and 0.033 μM, respectively (Fig. 1A, D). Here, ALK is linked to lung adenocarcinoma.